These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14692524)

  • 1. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
    Tsimberidou AM; Giles FJ; Kantarjian HM; Keating MJ; O'Brien SM
    Leuk Lymphoma; 2003 Oct; 44(10):1719-25. PubMed ID: 14692524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
    Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
    Szatrowski TP; Dodge RK; Reynolds C; Westbrook CA; Frankel SR; Sklar J; Stewart CC; Hurd DD; Kolitz JE; Velez-Garcia E; Stone RM; Bloomfield CD; Schiffer CA; Larson RA
    Cancer; 2003 Mar; 97(6):1471-80. PubMed ID: 12627512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
    Dinndorf P; Krailo M; Liu-Mares W; Frierdich S; Sondel P; Reaman G
    J Immunother; 2001; 24(6):511-6. PubMed ID: 11759074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
    Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
    J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
    Grossbard ML; Freedman AS; Ritz J; Coral F; Goldmacher VS; Eliseo L; Spector N; Dear K; Lambert JM; Blättler WA
    Blood; 1992 Feb; 79(3):576-85. PubMed ID: 1370636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
    Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
    Grossbard ML; Fidias P; Kinsella J; O'Toole J; Lambert JM; Blattler WA; Esseltine D; Braman G; Nadler LM; Anderson KC
    Br J Haematol; 1998 Jul; 102(2):509-15. PubMed ID: 9695966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
    Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
    Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
    Shah SA; Lambert JM; Goldmacher VS; Esber HJ; Levin JL; Chungi V; Zutshi A; Braman GM; Ariniello PD; Taylor JA
    Int J Immunopharmacol; 1993 Aug; 15(6):723-36. PubMed ID: 7691767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
    Furman RR; Grossbard ML; Johnson JL; Pecora AL; Cassileth PA; Jung SH; Peterson BA; Nadler LM; Freedman A; Bayer RL; Bartlett NL; Hurd DD; Cheson BD; ;
    Leuk Lymphoma; 2011 Apr; 52(4):587-96. PubMed ID: 21275630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma.
    Scadden DT; Schenkein DP; Bernstein Z; Luskey B; Doweiko J; Tulpule A; Levine AM
    Cancer; 1998 Dec; 83(12):2580-7. PubMed ID: 9874466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
    Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
    Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J
    J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
    Goulet AC; Goldmacher VS; Lambert JM; Baron C; Roy DC; Kouassi E
    Blood; 1997 Sep; 90(6):2364-75. PubMed ID: 9310487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
    Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
    Lynch TJ; Lambert JM; Coral F; Shefner J; Wen P; Blattler WA; Collinson AR; Ariniello PD; Braman G; Cook S; Esseltine D; Elias A; Skarin A; Ritz J
    J Clin Oncol; 1997 Feb; 15(2):723-34. PubMed ID: 9053498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.